A Leader Who Understands the Journey: Welcoming David Walsey as Bay Area Lyme Foundation’s New Executive Director

Bay Area Lyme Spotlight Series

 

“Science drives our mission, but patient stories remind us why the science matters.”

– David Walsey

As David Walsey steps into his new role as Executive Director of Bay Area Lyme Foundation, he brings more than professional expertise. He brings lived experience of diagnostic uncertainty, immune dysfunction, co-infections, and the long arc many families travel before answers emerge. For patients, caregivers, and supporters of Bay Area Lyme, David’s leadership signals both continuity and momentum: a future rooted in rigorous science, compassionate leadership, and hope grounded in progress. “It’s been a long journey to get here,” David says. “We’ve spent nearly a decade navigating tick-borne disease as a family. That experience changed everything for us.” Dana Parish interviewed David as part of our Ticktective video podcast series. Watch or listen to the complete interview.

When Symptoms Don’t Fit the Textbook

Nearly ten years ago, David’s son began experiencing a constellation of symptoms that defied easy explanation. Despite multiple medical evaluations, no unifying diagnosis emerged. When Lyme disease was finally identified, the family initially felt relief. “I thought this was a solvable, short-term problem,” David recalls. “You treat it, and life goes back to normal.”

Improving Lyme Diagnostics, Biomarkers, and Treatment: Inside Dr. Peter Gwynne’s Research

Peter Gwynne, PhD

Bay Area Lyme Leading the Way series

 

“I wanted to be doing work that was driven by clinical need… and there are a lot of clinical needs in Lyme disease.”

– Peter Gwynne, PhD

Peter Gwynne, PhDFor too many people with Lyme disease, the journey begins with uncertainty. A missed rash. A negative test. Symptoms that don’t make sense. A diagnosis that comes too late, or not at all. Bay Area Lyme Foundation believes this must change. And we believe change happens through funding rigorous science, innovative thinking, and supporting researchers willing to tackle the hardest questions head-on.

One of those scientists is Tufts researcher Peter Gwynne, PhD, a microbiologist whose work sits at the cutting edge of Lyme research and is the recipient of our 2022 Emerging Leader Award. We spoke with Dr. Gwynne to get an inside look at his work and understand how this may impact Lyme patients in the future. His focus is simple to state but complex to achieve: develop better diagnostics, identify meaningful biomarkers, and move the field toward treatments and even prevention strategies that could fundamentally reshape how Lyme disease is understood and managed.

Drawn to Lyme by the Urgency of the Need

Dr. Gwynne did not begin his career in Lyme disease. He trained in molecular microbiology, studying pathogens such as Salmonella and Staphylococcus, the bacteria responsible for serious infections, including those often acquired in hospital settings. But over time, he found himself seeking work that could make a tangible difference for patients.

A Foot-Tapper and Smile-Creator! Lyme Patient Releases New Jazz Album

Steve Erlich

Bay Area Lyme Spotlight Series

 

“Every listen helps fund Lyme research.”

– Steve Ehrlich

 

Steve Ehrlich emigrated to the San Francisco Bay Area from South Africa in 1989. Chronic Lyme Disease cut short his career in the software industry, and he turned to writing music. He has released two contemporary jazz albums with his virtual band, The Inter Section. He spends his days on his sofa writing music with his doggie, Frankie, hitting play and paws when needed. The second jazz album is now available on all the streaming apps, and, like his first album, all the proceeds will be donated to Bay Area Lyme.

We Need a New Generation of Lyme Doctors: James Bruzzese, MD, is Leading the Way

James Bruzzese

Bay Area Lyme Spotlights Series

 

“Some institutions are evolving in research and education, but it’s not translating to clinical practice.”

– James Bruzzese, MD

When James Bruzzese, MD, talks about Lyme disease, he doesn’t speak in abstractions. He speaks as a brother who watched his sister lose her ability to walk; a son who watched his father leave his job to become a full-time caregiver; and as a medical student who sat in lecture halls knowing that what was being taught about Lyme and tick-borne disease was grossly incomplete.

Now, as a young physician preparing to open a practice dedicated to treating Lyme and tick-borne disease patients in New York, James represents something the Lyme community urgently needs: a new generation of doctors who understand that Lyme is real, that patients deserve better, and that the status quo must be challenged.

“It Was Traumatic. We Thought We Might Lose Her.”

Bay Area Lyme Foundation Highlights Research Leadership and Momentum in Tick-Borne Disease, Names New Executive Director

FOR IMMEDIATE RELEASE

 

Bay Area Lyme Foundation Highlights Research Leadership and Momentum in Tick-Borne Disease, Names New Executive Director

Milestones include FDA-cleared diagnostics enabled by Lyme Disease Biobank, the launch of Bay Area Lyme Ventures, and 10 years since Lyme Disease Biobank provided its first samples, advancing the field

PORTOLA VALLEY, Calif., February 11, 2026Bay Area Lyme Foundation, a national nonprofit and leading sponsor of tick-borne disease research, today reflected on concrete progress in 2025 that demonstrates the maturation of more than a decade of investment in diagnostics, therapeutics, and research infrastructure for Lyme and other tick-borne diseases. As Bay Area Lyme Foundation-supported programs advance towards being available for clinicians and patients, the organization announced David A. Walsey, JD, LLM, as Executive Director. He has extensive experience offering strategic guidance to life sciences companies and a personal connection to Lyme disease that will help guide the foundation’s next phase of scientific translation and organizational growth.

In 2025, Bay Area Lyme Foundation reached an important inflection point as new diagnostic tests enabled by the foundation’s Lyme Disease Biobank secured FDA clearance. These new tests highlight the potential to move from discovery-stage research toward tools that can meaningfully improve patient care. The organization also launched Bay Area Lyme Ventures, an investment arm designed to help promising diagnostics and therapeutics move more efficiently from the laboratory into real-world use, while also creating the opportunity for returns to support future Bay Area Lyme Foundation research. This progress underscores the importance of the more than $30 million in research Bay Area Lyme Foundation has invested at leading academic and medical institutions such as Stanford, Johns Hopkins, Tulane, and Duke. Research supported by the foundation has produced over 70 peer-reviewed scientific publications and sustained collaboration across top research centers nationwide.

A New Year Call to Action After December 15, 2025, HHS Roundtable

Charlotte Mao, MD, MPH

Bay Area Lyme Spotlight Series

By Charlotte Mao, MD, MPH, Bay Area Lyme Foundation

Chronic Lyme Disease patients have been ignored for too long. That must end now.

– Charlotte Mao, MD, MPH

A Long-Overdue Moment of Recognition

Starting in 2026, Lyme disease and other tick-borne disease patients and their families have some reason to be encouraged by the growing recognition of the realities they face and the prospect of continued research to support new diagnostics and treatments.

HHS Lyme Disease Roundtable

 

The December 15, 2025, Department of Health and Human Services (HHS) roundtable marked something rare and long overdue: federal recognition of patient need, grounded in scientific evidence presented by researchers, clinicians, and patient advocates. But patients need more than another moment of recognition. They need results. In 2026, the question is whether that recognition will translate into sustained action, measurable progress, and real improvements in care.

Better Tests, Better Answers 

Jyotsna Shah, PhD, Ticktective

Bay Area Lyme Leading the Way Series

 

“The IGeneX test is far more sensitive than most commercially available tests for Lyme disease, detecting far more positive patients compared to standard two-tier ELISA or Western Blot tests,”

– Jyotsna Shah, PhD

Click here to watch or listen now

For people living with or who suspect Lyme disease, getting a clear diagnosis can feel like the hardest part. Symptoms often mimic those of other illnesses, and traditional tests miss many cases. 

In this episode of Ticktective™, Dr. Jyotsna Shah, President and Laboratory Director of IGeneX, shares with our host, Dana Parish, how her team is changing that—and how Bay Area Lyme Foundation helped make it possible. 

Dr. Shah explains how partnerships between innovative labs like IGenex, Bay Area Lyme Foundation, and our Lyme Disease Biobank are helping deliver faster, more accurate diagnostics—and new hope for patients who’ve struggled for years to find answers.

Ten Years of Data, One Clear Message: We Need to Do Better for Lyme Patients

Lyme Disease Biobank

Bay Area Lyme Leading the Way Series

By Liz Horn, PhD, MBI, Principal Investigator, Lyme Disease Biobank

“The window for effective antibiotic treatment is narrow. Miss it—because of a false negative test, because symptoms are dismissed, or because follow-up doesn’t happen—and patients can develop persistent Lyme, which can be debilitating.”

– Dr. Liz Horn

Lyme Disease Biobank patient sample

After a decade of collecting blood samples, testing the samples, tracking patient outcomes, and analyzing data from more than 800 participants, the numbers tell a powerful story about the gaps in our understanding of how we diagnose and treat early Lyme disease. And it’s made all the more urgent by this summer’s explosion in blacklegged (deer) tick populations across endemic areas.

Our latest Lyme Disease Biobank study looked at more than 250 patients with early Lyme disease on Long Island and in Central Wisconsin who provided a blood draw at enrollment and a second blood draw three months later. Published recently in Frontiers in Medicine, these 10 years of data confirm a few important points that have been known in the Lyme field for years, but the wider medical community may not be aware of.

LymeLnk and Bay Area Lyme Foundation Partner to Bridge the Gap Between Research and Public Awareness

LymeLnk

Bay Area Lyme Leading the Way Series

 

“Science moves minds and stories move hearts. This partnership connects two essential parts of the Lyme ecosystem: the research that advances medicine and the communication that inspires action. Together, we’re making education and prevention more accessible.” 

– Eva Scarano, Founder and Executive Director, LymeLnk

LymeLnk is a new nonprofit combating Lyme and tick-borne diseases (Lyme+) through community storytelling and education. Founded in 2024 at Parsons School of Design, LymeLnk was born out of founder Eva Scarano’s personal nine-year journey with Lyme+, during which she chose to create meaning from her isolated quest for health.

Eva’s Lyme+ journey began in 2016 with a textbook case: a bull’s-eye rash and flu-like symptoms. Among the fortunate few to receive a prompt diagnosis, she underwent three grueling months of antibiotics and supplemental treatment and was asymptomatic for two years. Everything changed in 2019 when she moved into a mold-infested apartment, triggering a collapse of her immune system—her Lyme markers were back and higher than ever. Years later, Eva had just begun graduate school at Parsons when she found herself at her “rock bottom.” Struggling to remember class material from the day prior or make it past 3:00 pm without a nap, she remained determined to continue her studies and reclaim her health.

Chronic Infections, Fertility, & Immunity: MIT Immunoengineer Makes Groundbreaking Lyme Discoveries

Michal Caspi Tal, PhD

Bay Area Lyme Spotlight Series

 

“There are significant increases after Lyme in fibroids and in endometriosis.”

– Michal Caspi Tal, PhD

Dancing Borrelia, Mikki Tal, PhD
Borrelia burgdorferi under attack from the immune system.

Imagine a world where Lyme disease isn’t something people fear, but something we actively prevent, or at least treat more precisely, especially for the many who suffer long after the tick bite. Dr. Michal “Mikki” Caspi Tal, immunoengineer and Associate Scientific Director at the MIT Center for Gynecology Pathology Research, is turning that possibility into reality. Her research isn’t just pushing boundaries, it’s rewriting the rules, especially in regards to women’s health.

“Nobody had looked…at what was happening to the uterus.”

– Michal Caspi Tal, PhD

Watching this incredible Ticktective™ interview with host Dana Parish is an absolute treasure trove of information—and if you or someone you know has ever wondered why some people recover from Lyme and others don’t, why symptoms linger, or why women disproportionately suffer, this is one of the most important conversations you’ll hear this year.

Click here to watch or listen now